School Of Basic And Applied Sciences

Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/17

Browse

Subject: search.filters.subject.Therapeutics

Search Results

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Type 2 Diabetes (T2DM) and Parkinson�s Disease (PD): a Mechanistic Approach
    (Springer, 2023-04-28T00:00:00) Sabari, S. Sri; Balasubramani, Kiruthika; Iyer, Mahalaxmi; Sureshbabu, Harysh Winster; Venkatesan, Dhivya; Gopalakrishnan, Abilash Valsala; Narayanaswamy, Arul; Senthil Kumar, Nachimuthu; Vellingiri, Balachandar
    Growing evidence suggest that there is a connection between Parkinson�s disease (PD) and insulin dysregulation in the brain, whilst the connection between PD and type 2 diabetes mellitus (T2DM) is still up for debate. Insulin is widely recognised to play a crucial role in neuronal survival and brain function; any changes in insulin metabolism and signalling in the central nervous system (CNS) can lead to the development of various brain disorders. There is accumulating evidence linking T2DM to PD and other neurodegenerative diseases. In fact, they have a lot in common patho-physiologically, including insulin dysregulation, oxidative stress resulting in mitochondrial dysfunction, microglial activation, and inflammation. As a result, initial research should focus on the role of insulin and its molecular mechanism in order to develop therapeutic outcomes. In this current review, we will look into the link between T2DM and PD, the function of insulin in the brain, and studies related to impact of insulin in causing T2DM and PD. Further, we have also highlighted the role of various insulin signalling pathway in both T2DM and PD. We have also suggested that T2DM-targeting pharmacological strategies as potential therapeutic approach for individuals with cognitive impairment, and we have demonstrated the effectiveness of T2DM-prescribed drugs through current PD treatment trials. In conclusion, this investigation would fill a research gap in T2DM-associated Parkinson�s disease (PD) with a potential therapy option. Graphical Abstract: [Figure not available: see fulltext.]. � 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
  • No Thumbnail Available
    Item
    Evolving strategies and application of proteins and peptide therapeutics in cancer treatment
    (Elsevier Masson s.r.l., 2023-05-05T00:00:00) Mukherjee, Anirban Goutam; Wanjari, Uddesh Ramesh; Gopalakrishnan, Abilash Valsala; Bradu, Pragya; Biswas, Antara; Ganesan, Raja; Renu, Kaviyarasi; Dey, Abhijit; Vellingiri, Balachandar; El Allali, Achraf; Alsamman, Alsamman M.; Zayed, Hatem; George Priya Doss, C.
    Several proteins and peptides have therapeutic potential and can be used for cancer therapy. By binding to cell surface receptors and other indicators uniquely linked with or overexpressed on tumors compared to healthy tissue, protein biologics enhance the active targeting of cancer cells, as opposed to the passive targeting of cells by conventional small-molecule chemotherapeutics. This study focuses on peptide medications that exist to slow or stop tumor growth and the spread of cancer, demonstrating the therapeutic potential of peptides in cancer treatment. As an alternative to standard chemotherapy, peptides that selectively kill cancer cells while sparing healthy tissue are developing. A mountain of clinical evidence supports the efficacy of peptide-based cancer vaccines. Since a single treatment technique may not be sufficient to produce favourable results in the fight against cancer, combination therapy is emerging as an effective option to generate synergistic benefits. One example of this new area is the use of anticancer peptides in combination with nonpeptidic cytotoxic drugs or the combination of immunotherapy with conventional therapies like radiation and chemotherapy. This review focuses on the different natural and synthetic peptides obtained and researched. Discoveries, manufacture, and modifications of peptide drugs, as well as their contemporary applications, are summarized in this review. We also discuss the benefits and difficulties of potential advances in therapeutic peptides. � 2023
  • No Thumbnail Available
    Item
    STAT signaling as a target for intervention: from cancer inflammation and angiogenesis to non-coding RNAs modulation
    (Springer Science and Business Media B.V., 2022-04-26T00:00:00) Tuli, Hardeep Singh; Sak, Katrin; Iqubal, Ashif; Garg, Vivek Kumar; Varol, Mehmet; Sharma, Uttam; Chauhan, Abhishek; Yerer, Mukerrem Betul; Dhama, Kuldeep; Jain, Manju; Jain, Aklank
    As a landmark, scientific investigation in cytokine signaling and interferon-related anti-viral activity, signal transducer and activator of transcription (STAT) family of proteins was first discovered in the 1990s. Today, we know that the STAT family consists of several transcription factors which regulate various molecular and cellular processes, including proliferation, angiogenesis, and differentiation in human carcinoma. STAT family members play an active role in transducing signals from cell membrane to nucleus through intracellular signaling and thus activating gene transcription. Additionally, they are also associated with the development and progression of human cancer by facilitating inflammation, cell survival, and resistance to therapeutic responses. Accumulating evidence suggests that not all STAT proteins are associated with the progression of human malignancy; however, STAT3/5 are constitutively activated in various cancers, including multiple myeloma, lymphoma, breast cancer, prostate hepatocellular carcinoma, and non-small cell lung cancer. The present review highlights how STAT-associated events are implicated in cancer inflammation, angiogenesis and non-coding RNA (ncRNA) modulation to highlight potential intervention into carcinogenesis-related cellular processes. � 2022, The Author(s), under exclusive licence to Springer Nature B.V.
  • No Thumbnail Available
    Item
    The journey of noncoding RNA from bench to clinic
    (Elsevier, 2021-01-30T00:00:00) Chhabra, Ravindresh
    The discovery of noncoding RNA (ncRNA) in the 90s completely changed our understanding of gene regulation. The ncRNAs specialize in regulating the gene expression, which enables them to induce a remarkable change in cellular pathways. The ncRNAs are categorized as small (<200 nucleotides) and long ncRNA (>200 nucleotides). The small ncRNAs are further classified as miRNAs, piwi-interacting RNAs (piRNAs), small interfering RNAs (siRNAs), and small nucleolar RNAs (snoRNAs). Both miRNAs and siRNAs silence gene expression by binding to their target mRNA but follow different mechanisms. piRNAs are responsible for bringing about transposon repression, and snoRNAs are mainly involved in the modification of rRNAs. The lncRNAs have diverse functions that range from chromatin modification to acting as a precursor of miRNAs to binding to mRNAs and blocking their translation. With such important functions in their repertoire, tightly regulated tissue-specific expression and differential expression in diseased conditions, the potential of ncRNAs as therapeutic targets and biomarkers is waiting to be exploited. As per the ClinicalTrials database of NLM, the number of clinical trial studies recorded for miRNAs, siRNAs, and lncRNAs are 861, 67, and 39, respectively. The siRNA therapeutic, Patisiran, became the first ncRNA to receive FDA approval for the treatment of a rare polyneuropathy in 2018. Miravirsen, an inhibitor of miR-122 is the first miRNA therapeutic drug, which is currently in multiple phase 2 clinical trials for the treatment of Hepatitis C. The lncRNA PCA3 was approved as a biomarker for prostate cancer in 2012. This chapter discusses the journey of ncRNA from bench to clinic with a few specific examples elaborating on the basic research involved in identifying them as biomarkers or therapeutic targets and bottlenecks in their clinical use. � 2021 Elsevier Inc. All rights reserved.
  • No Thumbnail Available
    Item
    Legume lectins: Potential use as a diagnostics and therapeutics against the cancer
    (Elsevier B.V., 2020) Gautam A.K.; Sharma D.; Sharma J.; Saini K.C.
    Legume lectins are carbohydrate-binding protein and widely distributed in a variety of species of leguminous plants and have drawn increased attention toward cancer. Nowadays, the lectins have been studied for the screening of potential biomarkers which increased its importance in cancer research. Few plant lectins have been shown to destroy cancer cells, suggesting that lectins may have biological potential in cancer treatments. In this review, we present a focused outline of legume lectins in descriptive their complex anti-cancer mechanisms on the bases of their properties of recognition and interacting specifically with carbohydrates binding sites. Existing reports suggested the binding of lectins to cancerous cells with their cell surface markers speculated by histochemistry in vitro and in vivo. In this review, we illuminate the use of legume lectins as a natural source for diagnostics and therapeutics purpose against cancer.